[VIRTUAL] First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies

[VIRTUAL] An Open-label, multicenter, Phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: Updated results from the skin cancer cohorts

[VIRTUAL] AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy

[VIRTUAL] Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist

[VIRTUAL] A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors

[VIRTUAL] Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma

[VIRTUAL] Scientific correlatives from LCCC 1525: A Phase II Study of a Priming Dose of Cyclophosphamide Prior to Pembrolizumab to Treat Metastatic Triple Negative Breast Cancer

[VIRTUAL] Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma

[VIRTUAL] Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors

[VIRTUAL] Enhancing T cell therapy for patients with relapsed/refractory Wilms Tumor

[VIRTUAL] Exploring resistance mechanism to pembrolizumab and ang-2 inhibitor trebananib (NCT03239145) using high-dimensional single-cell mass cytometry (CyTOF)

[VIRTUAL] The prognostic and predictive implications of the 12-chemokine score in muslce invasive bladder cancer

[VIRTUAL] Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180

[VIRTUAL] Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)